References
- StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med200535298799615758009
- StuppRHegiMEMasonWPEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
- JarvelaSHelinHHaapasaloJAmplifcation of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situhybridization: association with clinicopathological features and patient survivalNeuropathol Appl Neurobiol20063244145016866989
- Viana-PereiraMLopesJMLittleSAnalysis of EGFR overexpression, EGFR gene amplifcation and the EGFRvIII mutation in Portuguese high-grade gliomasAnticancer Res20082891392018507036
- MazzoleniSPolitiLSPalaMEpidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesisCancer Res201070197500751320858720
- MellinghoffIKWangMYVivancoIMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med20053532012202416282176
- RamakrishnanMSEswaraiahACrombetTNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMAbs200911414820046573
- Diaz-MiqueliAMartinezGSNimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunitiesOnco Targets Ther2013693194223926436
- BodeUMassiminoMBachFNimotuzumab treatment of malignant gliomasExpert Opin Biol Ther201212121649165923043252
- RamosTCFigueredoJCatalaMTreatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trialCancer Biol Ther20065437537916575203
- QinDOuGMoHImproved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical resultsInt J Radiat Oncol Biol Phys20015195996211704317
- Ramos-SuzarteMRodriguezNOlivaJP99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumours of epithelial origin, part II: clinical trials safety and diagnostic efficacyJ Nucl Med19994076877510319748
- HongJPengYLiaoYNimotuzumab prolongs survival in patients with malignant gliomas: a phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumabExp Ther Med20124115115723060940
- BartelsUWolffJGoreLPhase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine gliomaNeuro Oncol Epub5202014
- YangQYShenDSaiKNimotuzumab in combination with chemotherapy for patients with malignant gliomasZhonghua Zhong Liu Za Zhi2011333232235 Chinese21575527
- SolomonMTMirandaNJorrínENimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experienceCancer Biol Ther201415550450924521695
- MassiminoMBiassoniVMiceliRResults of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodJ Neurooncol2014118230531224696052
- WangYPanLShengXFNimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in Chinese patientsAsia Pac J Clin Oncol Epub1242014
- SaurezGCabanasRZaldívarMClinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007MEDICC Rev2009113273321483304
- CabanasRSaurezGRiosMTreatment of children with high grade glioma with nimotuzumab: a 5-year institutional experienceMAbs20135220220723575267
- SolomónRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trialBMC Cancer20131329923782513
- WestphalMBachFFinal results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide. ASCO Annual Meeting; June 1–5, 2012; Chicago, IL, USAJ Clin Oncol30Suppl Abstr 2033